Esperion Therapeutics Inc Cash Flow Conversion Efficiency
Esperion Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Esperion Therapeutics Inc (ESPR) has a cash flow conversion efficiency ratio of 0.009x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.29 Million) by net assets ($-451.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Esperion Therapeutics Inc (1999–2024)
Cash flow conversion efficiency of Esperion Therapeutics Inc from 1999 to 2024. This chart illustrates how Esperion Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Esperion Therapeutics Inc (ESPR) stock price for real-time trading data and today's change.
Esperion Therapeutics Inc Cash Flow Conversion Ratio Explained
Esperion Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Esperion Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Esperion Therapeutics Inc ranked by their cash flow conversion efficiency. Also see ESPR company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ningbo Ligong Online Monitoring Technology Co Ltd
SHE:002322
|
0.035x |
|
Allied Supreme Corp
TW:4770
|
0.006x |
|
Comintel Corporation Berhad
KLSE:7195
|
0.029x |
|
Shenzhen Comix Group Co Ltd
SHE:002301
|
0.017x |
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
|
0.031x |
|
McCormick & Company Incorporated
NYSE:MKC-V
|
0.007x |
|
Guangzhou Haoyang Electronic Co Ltd
SHE:300833
|
0.019x |
|
Tianma Bearing Group Co Ltd
SHE:002122
|
0.003x |
Annual Cash Flow Conversion Efficiency for Esperion Therapeutics Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Esperion Therapeutics Inc from 1999 to 2024. Review ESPR cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-388.72 Million | $-23.65 Million | 0.061x | -79.57% |
| 2023-12-31 | $-454.99 Million | $-135.49 Million | 0.298x | -44.85% |
| 2022-12-31 | $-323.78 Million | $-174.83 Million | 0.540x | -59.69% |
| 2021-12-31 | $-196.94 Million | $-263.81 Million | 1.340x | +51.18% |
| 2020-12-31 | $-96.13 Million | $-85.18 Million | 0.886x | +125.13% |
| 2019-12-31 | $19.95 Million | $-70.34 Million | -3.526x | -87.68% |
| 2018-12-31 | $79.12 Million | $-148.64 Million | -1.879x | -250.11% |
| 2017-12-31 | $244.69 Million | $-131.30 Million | -0.537x | -157.01% |
| 2016-12-31 | $228.60 Million | $-47.73 Million | -0.209x | -57.19% |
| 2015-12-31 | $287.26 Million | $-38.16 Million | -0.133x | +44.60% |
| 2014-12-31 | $133.55 Million | $-32.02 Million | -0.240x | +1.93% |
| 2013-12-31 | $74.09 Million | $-18.11 Million | -0.244x | -139.33% |
| 2012-12-31 | $-17.39 Million | $-10.81 Million | 0.622x | -58.49% |
| 2011-12-31 | $-6.06 Million | $-9.07 Million | 1.497x | +318.37% |
| 2002-12-31 | $38.74 Million | $-26.56 Million | -0.686x | -100.26% |
| 2001-12-31 | $66.50 Million | $-22.77 Million | -0.342x | -29.08% |
| 2000-12-31 | $67.69 Million | $-17.95 Million | -0.265x | +90.49% |
| 1999-12-31 | $2.81 Million | $-7.85 Million | -2.790x | -- |
About Esperion Therapeutics Inc
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary h… Read more